Needham downgrades Biogen to Hold on lack of share catalysts
Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...
Yahoo Finance5h
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...
Business Insider10h
Needham downgrades Biogen (BIIB) to a Hold
Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company’s shares closed last Friday at $159.99. Don't Miss our Black Friday Offers: ...
ETF Daily News14h
Biogen (NASDAQ:BIIB) Price Target Raised to $300.00
Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
BioSpace5d
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
BioPharma Dive2d
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
Biogen (NASDAQ:BIIB) Earns Peer Perform Rating from Analysts at Wolfe Research
Research analysts at Wolfe Research initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued ...
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Finanznachrichten2h
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ
OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership EC ...